Introduction {#s2}
============

HIV is a leading cause of morbidity and mortality globally [@pmed.1001496-Murray1]. Despite considerable progress in controlling the epidemic, there were approximately 2.2 million new HIV infections, 1.7 million HIV-related deaths, and 34.2 million people with HIV worldwide in 2011; 1.5 million of these new HIV infections, 1.2 million of the HIV deaths, and 23.5 million of the people living with HIV were in Africa [@pmed.1001496-Joint1]. Given the urgency to act on the epidemic, all United Nations member states agreed to achieve the following HIV targets by 2015: (1) reduce sexual and parenteral HIV transmission by 50%, (2) eliminate vertical HIV transmission, (3) reduce tuberculosis deaths among people with HIV by 50%, and (4) deliver antiretroviral therapy (ART) to 15 million people [@pmed.1001496-United1]. Achieving these targets will require people at risk of HIV to learn their status and link to prevention and care services.

In an effort to expand access to prevention and care services, World Health Organization (WHO) guidelines recommend provider-initiated HIV testing and counselling (HTC) for all people seen in all health facilities in generalised epidemics (i.e., antenatal HIV prevalence ≥1%) and in specific facilities in concentrated epidemics [@pmed.1001496-World1]. While provider-initiated HTC programmes have been successful in identifying previously undiagnosed individuals in generalised epidemics, they may not reach all people at risk of HIV acquisition [@pmed.1001496-Roura1],[@pmed.1001496-Hensen1]. Indeed, the latest Demographic and Health Surveys from 29 sub-Saharan African countries, representing approximately half of the global burden of HIV, indicate that only 15% of adults received results from an HIV test in the previous year [@pmed.1001496-Staveteig1]. This low coverage is recognised as a critical barrier to scaling up HIV prevention and care interventions. Furthermore, people living with HIV are often diagnosed late in the course of their disease, resulting in avoidable morbidity, mortality, and transmission of the virus. [@pmed.1001496-Egger1].

The reasons for the current low coverage of HTC are various and include service, patient, and demographic barriers [@pmed.1001496-Matovu1],[@pmed.1001496-World2]. For example, in generalised epidemics women have higher rates of testing than men and adolescents, perhaps because of their contact with reproductive and antenatal health services [@pmed.1001496-Staveteig1]. Implementation of provider-initiated HTC guidance remains a priority for countries. However, because many people have limited contact with healthcare providers, HTC provision in health facilities alone is insufficient to achieve national and global targets. Although previous research has reviewed home-based HTC [@pmed.1001496-Bateganya1],[@pmed.1001496-Sabapathy1], the impact of all community-based HTC approaches has not been systematically reviewed. The objective of this study was to systematically review all community-based HTC approaches to inform global and national HIV programming.

Methods {#s3}
=======

Conduct of Systematic Review {#s3a}
----------------------------

This systematic review was conducted in accordance with the PRISMA statement using a pre-defined protocol (International Prospective Register of Systematic Reviews identification number: CRD42012002554; [Text S1](#pmed.1001496.s006){ref-type="supplementary-material"} and [Protocol S1](#pmed.1001496.s001){ref-type="supplementary-material"}) [@pmed.1001496-Liberati1],[@pmed.1001496-Suthar1]. The PubMed database was searched on 4 March 2013, and Embase and WHO Global Index Medicus were systematically searched on 10 April 2012, without language, geographic, publication, date, or any other restrictions. In addition, the WHO International Clinical Trials Registry Platform, the Cochrane Central Register of Controlled Trials, the International Standard Randomised Controlled Trial Number Register, and ClinicalTrials.gov were systematically searched without language, publication, or date restrictions on 3 September 2012. Experts in the field were contacted to identify unpublished research and ongoing studies, and bibliographies of relevant studies were screened.

Study Definitions {#s3b}
-----------------

Community-based HTC was defined as HTC outside of health facilities. Facility-based HTC approaches were defined as those in healthcare sites (e.g., health facilities, hospitals, and fixed, stand-alone voluntary counselling and testing sites). Eleven different community-based HTC approaches were reviewed in this study: (1) door-to-door testing (systematically offering HTC to homes in a catchment area), (2) mobile testing for the general population (offering HTC via a mobile HTC service in areas visited by the general public, such as shopping centres, transport hubs, or roadside restaurants), (3) index testing (offering HTC to household members of people with HIV and persons who may have been exposed to HIV such as spouses, sexual partners, or children of people with HIV); (4) mobile testing for men who have sex with men (MSM), (5) mobile testing for people who inject drugs (PWID), (6) mobile testing for female sex workers (FSW), (7) mobile testing for adolescents, (8) self-testing, (9) workplace HTC, (10) church-based HTC, and (11) school-based HTC.

Several outcomes were analysed in this study. Uptake was calculated by dividing the number of individuals accepting HTC by the number of individuals offered HTC. The proportion of first-time testers was calculated by dividing the number of people reporting receiving their first HIV test by the total number of people tested. The proportion of participants with a CD4 count greater than 350 cells/µl was calculated among participants with HIV who had their CD4 count measured. Two steps of the retention continuum were assessed: (1) CD4 measurement (among all participants found to have HIV) and (2) initiation of ART (among participants eligible per national guidelines). In studies with a comparator arm, the HIV positivity rate was calculated by dividing the number of individuals found to be HIV positive by the number of individuals tested. HTC coverage was calculated by dividing the number of people tested by the total number of people living in the catchment area for the community-based HTC approach. HIV incidence was calculated by dividing the risk of infection in communities with access to community- and facility-based HTC by the risk of infection in communities with access to only facility-based HTC. Some of the outcomes were not independent. For example, the number of people tested was the denominator for the HIV positivity rate and first-time testers and also the numerator for HTC coverage. Moreover, the number of people living with HIV was the numerator for the HIV positivity rate and also the denominator for calculating the first step of the retention continuum (CD4 measurement). The cost per person tested was approximated by dividing the economic costs incurred during HTC in studies by the total number of people tested. Costs were adjusted for inflation from the year the costs were estimated to 2012 United States dollars using the US Bureau of Labor Statistics\' inflation calculator [@pmed.1001496-United2].

Search Strategy and Selection Criteria {#s3c}
--------------------------------------

The search strategies ([Table S1](#pmed.1001496.s002){ref-type="supplementary-material"}) were designed with the assistance of a librarian to identify studies including community-based HTC. Following recommendations from PRISMA, eligibility criteria were based on key study characteristics: population, intervention, comparator, outcome, and design [@pmed.1001496-Liberati1]. Specifically, studies were included when (1) the study population included people in generalised, concentrated, or low-level HIV epidemics; (2) the intervention was community-based HTC offered in combination with a background of facility-based HTC; (3) the comparator was facility-based HTC; (4) the outcome(s) included uptake, proportion of people reporting receiving their first HIV test, CD4 value at diagnosis, rates of linkage to care, HIV positivity rate, HTC coverage, HIV incidence, or cost per person tested; and (5) the study design was a randomised trial or observational cohort study. Given the lack of comparative studies for community-based HTC, studies without a comparator arm were also included if they met the remaining eligibility criteria.

A. B. S., N. F., and O. A. independently screened the abstracts of all articles identified via the literature database searches and then compared the full texts of all articles selected during screening against the inclusion criteria. Disagreements were resolved by discussion. J. S. R. and A. K. S. repeated the same process for the clinical trial registries.

Data Extraction {#s3d}
---------------

A. B. S., J. S. R., and A. K. S. completed the data extraction of characteristics of study participants, community-based testing approaches, outcomes, and quality assessment using a standardised extraction form.

Quality Assessment {#s3e}
------------------

The Newcastle-Ottawa Quality Assessment Scale was used to assess bias in studies with a comparator arm included in pooled analyses [@pmed.1001496-Wells1]. This scale rates studies based on eight criteria in three sources of bias. We modified this scale to remove one criterion, demonstration that the outcome of interest was not present at the start of study, since a previous HIV test may not affect all the outcomes analysed in this article. The Cochrane Collaboration\'s "risk of bias" tool was used to assess bias in randomised trials with a comparator arm [@pmed.1001496-The1].

Statistical Analyses {#s3f}
--------------------

Outcome proportions from studies meeting inclusion criteria were stabilised using the Freeman-Tukey-type arcsine square-root transformation and then pooled to summarise the proportion of participants who (1) accepted different community-based HTC approaches, (2) reported receiving their first HIV test, (3) had CD4 counts measured after diagnosis, (4) were diagnosed with HIV with a CD4 count above 350 cells/µl, and (5) initiated ART after their CD4 count indicated they were eligible for treatment [@pmed.1001496-Freeman1],[@pmed.1001496-Newcombe1]. Pooled relative risks (RRs) were used to compare participants of community- and facility-based HTC with respect to uptake, proportion of first-time testers, the HIV positivity rate, proportion with CD4 counts above 350 cells/µl, and HTC coverage. Random-effects models were used for all analyses. Given the differences in HIV epidemiology, sexual mixing patterns, transmission factors, and healthcare utilisation rates for key populations, key population outcome data were reported individually and not pooled. *I* ^2^ statistics were used to measure heterogeneity [@pmed.1001496-Higgins1]. *I* ^2^ statistics near 25% indicate low heterogeneity, values near 50% indicate moderate heterogeneity, and those above 75% indicate high heterogeneity [@pmed.1001496-Higgins2]. All analyses were completed in STATA version 12.0.

Results {#s4}
=======

Search Results {#s4a}
--------------

108 articles, describing studies conducted from 1987 to 2012 and including 864,651 participants completing HTC, met the eligibility criteria ([Table 1](#pmed-1001496-t001){ref-type="table"}; [Figure 1](#pmed-1001496-g001){ref-type="fig"}). Two articles were randomised trials [@pmed.1001496-Corbett1],[@pmed.1001496-Sweat1], and the rest were observational in design. Data from one multi-centre cluster-randomised trial were stratified into three studies (based on the country where the testing was offered) [@pmed.1001496-Sweat1], data from three articles were stratified based on the year community-based HTC was offered [@pmed.1001496-Angotti1]--[@pmed.1001496-Slesak1], and data from four articles were stratified based on the community-based HTC approach used [@pmed.1001496-Ahmed1]--[@pmed.1001496-Shapiro1]. Given that 108 articles provided data from 108 studies and there were nine additional studies after stratification, there were a total of 117 studies included ([Table S4](#pmed.1001496.s005){ref-type="supplementary-material"}). 76 studies were from Africa, 28 were from North America (excluding Central America), six were from Asia, four were from Central and South America, three were from Europe, and one was from Australia. The clinical trial registers identified ten ongoing trials: one on index testing [@pmed.1001496-University1], one on mobile testing [@pmed.1001496-National1], five on door-to-door testing [@pmed.1001496-Liverpool1]--[@pmed.1001496-London1], one on self-testing [@pmed.1001496-University3], and two on community-based testing for key populations [@pmed.1001496-New1],[@pmed.1001496-University4].

![Flow of information through different phases of the review.](pmed.1001496.g001){#pmed-1001496-g001}

10.1371/journal.pmed.1001496.t001

###### Summary of study participants and methods.

![](pmed.1001496.t001){#pmed-1001496-t001-1}

  Testing Model      Number of Studies   Total Number Tested   Median Year Study Conducted (IQR)[a](#nt101){ref-type="table-fn"}   Number of Males (Percent)[b](#nt102){ref-type="table-fn"}   Number of Studies with a Demand Creation Component (Percent)   Number of Studies Providing Incentives (Percent)   Number of Studies with a Multi-Disease Component (Percent)   Number of Studies Linking People with HIV to Care (Percent)
  ----------------- ------------------- --------------------- ------------------------------------------------------------------- ----------------------------------------------------------- -------------------------------------------------------------- -------------------------------------------------- ------------------------------------------------------------ -------------------------------------------------------------
  Index                      8                 12,400                                 2005 (2004 to 2006)                                                5,556 (45.3)                                                     0 (0)                                                   1 (12.5)                                                2 (25.0)                                                     5 (62.5)
  Door-to-door              33                 595,389                                2008 (2004 to 2009)                                               247,439 (45.9)                                                  11 (33.3)                                                 2 (6.1)                                                 8 (24.2)                                                     19 (57.6)
  Mobile                    34                 193,602                                2008 (2005 to 2009)                                                86,989 (44.9)                                                  20 (60.6)                                                 7 (20.6)                                               15 (44.1)                                                     16 (47.1)
  Key populations           29                 41,451                                 2005 (2002 to 2008)                                                12,866 (61.9)                                                  10 (34.5)                                                15 (51.7)                                                9 (31.0)                                                     16 (55.2)
  Self                       3                  1,779                                 2006 (2002 to 2008)                                                1,113 (62.6)                                                    1 (33.3)                                                 2 (66.7)                                                0 (0.0)                                                      1 (33.3)
  Workplace                  6                 17,352                                 2004 (2003 to 2009)                                                9,817 (67.0)                                                    2 (33.3)                                                 1 (16.7)                                                4 (66.7)                                                     3 (50.0)
  School                     4                  2,678                                 2009 (2005 to 2009)                                                 957 (42.2)                                                     2 (50.0)                                                 0 (0.0)                                                 2 (50.0)                                                     3 (75.0)

The midpoint was used for studies that took place over several years.

Among studies that included gender data.

IQR, interquartile range.

The percentage of participants who were male was 45.3% for index testing, 45.9% for door-to-door testing, 44.9% for mobile testing, 62.6% for self-testing, 67.0% for workplace testing, and 42.2% for school-based testing ([Table 1](#pmed-1001496-t001){ref-type="table"}). Excluding studies including only MSM or only FSW, 62.9% of testers were male in mobile testing for key populations ([Table 1](#pmed-1001496-t001){ref-type="table"}). Population-level HTC efforts found that implementation of community-based HTC increases the number of couples receiving testing ([Table 2](#pmed-1001496-t002){ref-type="table"}).

10.1371/journal.pmed.1001496.t002

###### Percentage of clients received as couples in community-wide testing efforts.

![](pmed.1001496.t002){#pmed-1001496-t002-2}

  Study (Testing Approach)                                   Country      Year   Number Tested as a Couple   Number Tested   Percent Tested as a Couple
  ------------------------------------------------------- -------------- ------ --------------------------- --------------- ----------------------------
  Sweat (facility-based) [@pmed.1001496-Sweat1]              Thailand     2007             1,472                 2,721                 54.1%
  Sweat (mobile) [@pmed.1001496-Sweat1]                      Thailand     2007             2,574                10,464                 24.6%
  Tumwesigye (door-to-door) [@pmed.1001496-Tumwesigye1]       Uganda      2007            35,634                264,966                13.4%
  Sweat (facility-based) [@pmed.1001496-Sweat1]              Zimbabwe     2007              61                    610                  10.0%
  Naik (door-to-door) [@pmed.1001496-Naik1]                South Africa   2010              458                  5,086                  9.1%
  Lugada (mobile) [@pmed.1001496-Lugada2]                     Kenya       2008             3,296                47,173                  7.0%
  Sweat (facility-based) [@pmed.1001496-Sweat1]              Tanzania     2007              24                    685                   3.5%
  Sweat (mobile) [@pmed.1001496-Sweat1]                      Zimbabwe     2007              223                  6,579                  3.4%
  Sweat (mobile) [@pmed.1001496-Sweat1]                      Tanzania     2007              54                   2,832                  1.9%

Uptake {#s4b}
------

61 studies reported uptake of different community-based testing approaches among 713,632 participants: seven studies evaluated index testing among 12,052 participants [@pmed.1001496-Menzies1],[@pmed.1001496-Shapiro1],[@pmed.1001496-Armbruster1]--[@pmed.1001496-Nelson1], three evaluated self-testing among 1,839 participants [@pmed.1001496-Choko1]--[@pmed.1001496-Spielberg1], 14 evaluated mobile HTC among 79,475 participants [@pmed.1001496-Slesak1],[@pmed.1001496-Maheswaran1],[@pmed.1001496-Bahwere1]--[@pmed.1001496-vanRooyen1], 28 evaluated door-to-door testing among 555,267 participants [@pmed.1001496-Angotti1],[@pmed.1001496-Helleringer1],[@pmed.1001496-Maheswaran1],[@pmed.1001496-Shapiro1],[@pmed.1001496-Cherutich1]--[@pmed.1001496-Wolff1], six evaluated workplace HTC among 62,406 participants [@pmed.1001496-Corbett1],[@pmed.1001496-Feeley1]--[@pmed.1001496-VanderBorght1], and three evaluated school-based HTC among 2,593 participants [@pmed.1001496-HenryReid1]--[@pmed.1001496-Patel1] ([Figure 2](#pmed-1001496-g002){ref-type="fig"}). The percentage of participants accepting HTC was 88.2% for index testing (95% confidence interval \[CI\] 80.5%--95.9%; *I* ^2^ 99.7%, 95% CI 99.7%--99.8%; [Figure 3](#pmed-1001496-g003){ref-type="fig"}), 87.1% for self-testing (95% CI 85.1%--89.0%; *I* ^2^ 28.8%, 95% CI 0%--92.6%; [Figure 4](#pmed-1001496-g004){ref-type="fig"}), 86.8% for mobile HTC (95% CI 85.6%--88.1%; *I* ^2^ 99.9%, 95% CI 99.9%--99.9%; [Figure 5](#pmed-1001496-g005){ref-type="fig"}), 80.0% for door-to-door HTC (95% CI 76.9%--83.1%; *I* ^2^ 99.9%, 95% CI 99.9%--99.9%; [Figure 6](#pmed-1001496-g006){ref-type="fig"}), 67.4% for workplace HTC (95% CI 32.8%--100.0%; *I* ^2^ 100%, 100.0%--100.0%; [Figure 7](#pmed-1001496-g007){ref-type="fig"}), and 62.1% for school-based HTC (95% CI 39.6%--84.5%; *I* ^2^ 99.0%, 95% CI 98.5%--99.4%; [Figure 8](#pmed-1001496-g008){ref-type="fig"}). Uptake was higher in community-based HTC compared to providing vouchers to participants for facility-based HTC (RR 10.65, 95% CI 6.27--18.08; *I* ^2^ 96.1%; [Figure 9](#pmed-1001496-g009){ref-type="fig"}) [@pmed.1001496-Corbett1],[@pmed.1001496-Lugada1].

![Pooled uptake of community-based HTC approaches.\
Bars indicate 95% CIs.](pmed.1001496.g002){#pmed-1001496-g002}

![Uptake of index HTC.](pmed.1001496.g003){#pmed-1001496-g003}

![Uptake of self-testing.](pmed.1001496.g004){#pmed-1001496-g004}

![Uptake of mobile HTC.](pmed.1001496.g005){#pmed-1001496-g005}

![Uptake of door-to-door HTC.\
Asterisk: data reported were exclusively from children aged 18 mo.--13 y.](pmed.1001496.g006){#pmed-1001496-g006}

![Uptake of workplace HTC.\
Asterisk: data reported were from the Democratic Republic of Congo, Rwanda, Burundi, Congo, and Nigeria.](pmed.1001496.g007){#pmed-1001496-g007}

![Uptake of school-based HTC.](pmed.1001496.g008){#pmed-1001496-g008}

![Pooled relative risks of community-based HTC versus facility-based HTC.\
The numerator for all RRs was the risk of an outcome in community-based testing, while the denominator was the risk of an outcome in facility-based testing.](pmed.1001496.g009){#pmed-1001496-g009}

19 studies reported uptake among 41,110 participants in key populations, including 16,725 MSM [@pmed.1001496-Lister1]--[@pmed.1001496-Sy1], 4,681 PWID [@pmed.1001496-Spielberg2],[@pmed.1001496-Centers2]--[@pmed.1001496-OConnor1], 81 FSW [@pmed.1001496-Nhurod1], 13,240 adolescents [@pmed.1001496-Bell1],[@pmed.1001496-Robbins1], and 6,383 individuals from combinations of key populations. The percentage accepting HTC was 99.7% among FSW, ranged from 13.7% to 94.5% among PWID, ranged from 9.4% to 95.0% among MSM, and ranged from 33.9% to 96.6% among adolescents ([Figure 10](#pmed-1001496-g010){ref-type="fig"}). One study reported an uptake percentage of 95.2% among PWID and FSW [@pmed.1001496-Liang1], another reported an uptake percentage of 75.1% among PWID, FSW, and MSM [@pmed.1001496-Bucher1], and another reported an uptake percentage of 60.0% among PWID and MSM [@pmed.1001496-Bowles1]. Uptake was higher for community-based testing than for facility-based testing among FSW (RR 1.10, 95% CI 1.03--1.17) [@pmed.1001496-Nhurod1] and MSM (RR 1.53, 95% CI 1.42--1.65) [@pmed.1001496-Smith1] ([Figure 11](#pmed-1001496-g011){ref-type="fig"}).

![Uptake of community-based HTC approaches among key populations.](pmed.1001496.g010){#pmed-1001496-g010}

![Relative risks of community-based HTC versus facility-based HTC among key populations.\
The numerator for all RRs was the risk of an outcome in community-based testing, while the denominator was the risk of an outcome in facility-based testing.](pmed.1001496.g011){#pmed-1001496-g011}

First-Time Testers {#s4c}
------------------

33 studies reported the HTC history among 597,016 participants in community-based HTC approaches [@pmed.1001496-Sweat1],[@pmed.1001496-Helleringer1],[@pmed.1001496-Ahmed1]--[@pmed.1001496-Menzies1],[@pmed.1001496-Were1],[@pmed.1001496-Choko1],[@pmed.1001496-Chamie1],[@pmed.1001496-Darling1]--[@pmed.1001496-Kranzer1],[@pmed.1001496-Ostermann1]--[@pmed.1001496-Dalal1],[@pmed.1001496-Kimaiyo1],[@pmed.1001496-Kranzer2],[@pmed.1001496-Mutale1],[@pmed.1001496-Naik1],[@pmed.1001496-Sekandi1],[@pmed.1001496-Tumwesigye1],[@pmed.1001496-Kwena1],[@pmed.1001496-Grabbe1]--[@pmed.1001496-Truong1]. 62.2% (95% CI 58.0%--66.4%; *I* ^2^ 99.9%, 95% CI 99.9%--99.9%; [Figure 12](#pmed-1001496-g012){ref-type="fig"}) of participants at community-based HTC sites reported receiving their first HIV test. In the nine studies with a facility-based comparator arm, a larger proportion of participants reported receiving their first HIV test at community-based HTC than at facility-based HTC (RR 1.23, 95% CI 1.06--1.42; *I* ^2^ 99.8%, 95% CI 99.8%--99.9%; [Figure 9](#pmed-1001496-g009){ref-type="fig"}) [@pmed.1001496-Sweat1],[@pmed.1001496-Ahmed1],[@pmed.1001496-Menzies1],[@pmed.1001496-Grabbe1],[@pmed.1001496-Lahuerta1],[@pmed.1001496-Spielberg3].

![First-time testers in community-based testing approaches.](pmed.1001496.g012){#pmed-1001496-g012}

17 studies reported the HTC history of 25,311 participants from key populations receiving community-based HTC [@pmed.1001496-Ahmed1],[@pmed.1001496-Lister1],[@pmed.1001496-Spielberg2],[@pmed.1001496-Balaji1],[@pmed.1001496-Smith1],[@pmed.1001496-Centers2],[@pmed.1001496-Bucher1],[@pmed.1001496-Lahuerta1],[@pmed.1001496-Bingham1]--[@pmed.1001496-Stein1]. 9% to 79% of participants reported receiving their first HIV test ([Figure 13](#pmed-1001496-g013){ref-type="fig"}). Five of these studies included a facility-based comparator arm ([Figure 11](#pmed-1001496-g011){ref-type="fig"}). There were more first-time testers in community-based HTC than facility-based HTC for two study populations of MSM (RR 2.24, 95% CI 1.27--3.93 [@pmed.1001496-Bingham1] and RR 1.37, 95% CI 1.18--1.59 [@pmed.1001496-Lahuerta1]); however, there were fewer first-time testers in community-based HTC for a different study population of MSM (RR 0.33, 95% CI 0.26--0.43 [@pmed.1001496-Smith1]). There were more first-time testers in community-based HTC than facility-based HTC for a study population including PWID and MSM (RR 1.10, 95% CI 1.08--1.13 [@pmed.1001496-DiFranceisco1]); however, there was no difference in the proportion of first-time testers for a study population of FSW (RR 0.97, 95% CI 0.72--1.30 [@pmed.1001496-Lahuerta1]).

![First time testers in community-based testing approaches for key populations.](pmed.1001496.g013){#pmed-1001496-g013}

HIV Positivity Rate {#s4d}
-------------------

14 studies included data on the HIV positivity rate among people testing in community-based approaches relative to people testing in facility-based approaches [@pmed.1001496-Corbett1],[@pmed.1001496-Sweat1],[@pmed.1001496-Ahmed1],[@pmed.1001496-Menzies1],[@pmed.1001496-Lugada1],[@pmed.1001496-Gonzalez1],[@pmed.1001496-HenryReid1],[@pmed.1001496-Lahuerta1],[@pmed.1001496-Hood1]--[@pmed.1001496-vanSchaik1]. Overall, the HIV positivity rate was lower in community-based approaches relative to facility-based approaches (RR 0.59, 95% CI 0.37--0.96; *I* ^2^ 99.6%, 95% CI 99.6%--99.7%; [Figure 9](#pmed-1001496-g009){ref-type="fig"}). The median number needed to screen to identify one person with HIV in community- and facility-based HTC was 17 (range 3--86) and 6 (range 4--154), respectively ([Table 3](#pmed-1001496-t003){ref-type="table"}). The number needed to screen with community-based testing was highest in settings with a low national HIV prevalence: 54 in Thailand and 86 in Guatemala [@pmed.1001496-Sweat1],[@pmed.1001496-Lahuerta1].

10.1371/journal.pmed.1001496.t003

###### Number needed to screen to identify a person with HIV in studies offering community- and facility-based HTC.

![](pmed.1001496.t003){#pmed-1001496-t003-3}

  Study (Testing Approach)                               Country      Community-Based HTC   Facility-Based HTC                                      
  --------------------------------------------------- -------------- --------------------- -------------------- ------ ---- ------- -------- ------ -----
  Ahmed (mobile) [@pmed.1001496-Ahmed1]                  Nigeria             1,049                9,409          0.11   9    2,104   16,587   0.13    8
  Corbett (workplace) [@pmed.1001496-Corbett1]           Zimbabwe             673                 3,395          0.20   5     560     3045    0.18    5
  Gonzalez (door-to-door) [@pmed.1001496-Gonzalez1]     Mozambique            270                  718           0.38   3     155     660     0.23    4
  Hood (mobile) [@pmed.1001496-Hood1]                    Botswana            2,493                21,237         0.12   9    3,743   26,653   0.14    7
  Lahuerta (mobile) [@pmed.1001496-Lahuerta1]           Guatemala              6                   513           0.01   86    91     1,233    0.07   14
  Lugada (index) [@pmed.1001496-Lugada1]                  Uganda              189                 2,678          0.07   14    45      260     0.17    6
  McCoy (mobile) [@pmed.1001496-McCoy1]                     US                 9                   243           0.04   27    16     2,471    0.01   154
  Menzies (index) [@pmed.1001496-Menzies1]                Uganda              121                 2,011          0.06   17   1,834   9,579    0.19    5
  Menzies (door-to-door) [@pmed.1001496-Menzies1]         Uganda             2,502                49,470         0.05   20   6,108   22,482   0.27    4
  Sweat (mobile) [@pmed.1001496-Sweat1]                  Tanzania             86                  2,341          0.04   27    40      579     0.07   14
  Sweat (mobile) [@pmed.1001496-Sweat1]                  Zimbabwe             693                 5,437          0.13   8     132     602     0.22    5
  Sweat (mobile) [@pmed.1001496-Sweat1]                  Thailand             173                 9,361          0.02   54    92     2,721    0.03   30
  van Schaik (mobile) [@pmed.1001496-vanSchaik1]       South Africa           147                 2,499          0.06   17    273    1,321    0.21    5

The Henry-Reid et al. [@pmed.1001496-HenryReid1] study was excluded since it did not find any people with HIV among the 20 school participants screened.

Six community-based testing studies for key populations included a facility-based comparator arm ([Figure 11](#pmed-1001496-g011){ref-type="fig"}). Studies including FSW and a combination of PWID and MSM found no difference in the positivity rate for community- versus facility-based approaches (FSW, RR 0.62, 95% CI 0.29--1.34 [@pmed.1001496-Lahuerta1] and RR 1.39, 95% CI 0.85--2.29 [@pmed.1001496-Nhurod1]; PWID and MSM, RR 1.13, 95% CI 0.91--1.39 [@pmed.1001496-DiFranceisco1]). There was a lower positivity rate among a study population of MSM (RR 0.09, 95% CI 0.03--0.33 [@pmed.1001496-Lahuerta1]) and among a study population including PWID, FSW, and MSM (RR 0.51, 95% CI 0.28--0.94 [@pmed.1001496-Shrestha1]). There was also a higher positivity rate among a study population of MSM (RR 2.37, 95% CI 1.35--4.15 [@pmed.1001496-Yin1]). The number needed to screen to identify one person with HIV varied depending on the key population and study setting ([Table 4](#pmed-1001496-t004){ref-type="table"}).

10.1371/journal.pmed.1001496.t004

###### Number needed to screen to identify a person with HIV in studies offering community- and facility-based HTC to key populations.
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  Study                                         Key Population(s)     Country    Community-Based HTC   Facility-Based HTC                                     
  -------------------------------------------- -------------------- ----------- --------------------- -------------------- ------ ----- ----- -------- ------ -----
  Lahuerta [@pmed.1001496-Lahuerta1]                   MSM           Guatemala            3                   385           0.01   128   12     144     0.08   12
  Yin [@pmed.1001496-Yin1]                             MSM             China             23                   421           0.05   18    24    1,041    0.02   43
  Lahuerta [@pmed.1001496-Lahuerta1]                   FSW           Guatemala           17                   438           0.04   26    10     161     0.06   16
  Nhurod [@pmed.1001496-Nhurod1]                       FSW           Thailand            17                    81           0.21    5    48     319     0.15    7
  DiFranceisco [@pmed.1001496-DiFranceisco1]       MSM and PWID         US               110                 12,171         0.01   111   401   50,128   0.01   125
  Shrestha [@pmed.1001496-Shrestha1]            MSM, PWID, and FSW      US               20                  1,679          0.01   84    20     855     0.02   43

CD4 Counts {#s4e}
----------

18 studies reported the CD4 counts of 8,993 participants found to be HIV-positive using point-of-care or standard lab diagnostics [@pmed.1001496-Menzies1],[@pmed.1001496-Shapiro1],[@pmed.1001496-Chamie1],[@pmed.1001496-Kranzer1],[@pmed.1001496-Lugada2],[@pmed.1001496-Cherutich1],[@pmed.1001496-Dalal1],[@pmed.1001496-Tumwesigye1],[@pmed.1001496-vanRooyen2],[@pmed.1001496-Feeley1],[@pmed.1001496-Nglazi1],[@pmed.1001496-vanSchaik1],[@pmed.1001496-Govindasamy1]--[@pmed.1001496-Wachira1]. 56.7% (95% CI 49.6%--63.9%; *I* ^2^ 97.6%, 95% CI 97.0%--98.1%; [Figure 14](#pmed-1001496-g014){ref-type="fig"}) of participants testing positive had CD4 counts above 350 cells/µl. In the five studies with a facility-based HTC comparator arm, more participants in community-based HTC approaches had CD4 counts above 350 cells/µl than in facility-based approaches (RR 1.42, 95% CI 1.16--1.74; *I* ^2^ 94.8%, 95% CI 90.5%--97.1%; [Figure 9](#pmed-1001496-g009){ref-type="fig"}) [@pmed.1001496-Menzies1],[@pmed.1001496-vanSchaik1],[@pmed.1001496-Granich1],[@pmed.1001496-Wachira1].

![Pooled percentage of community-based HTC participants with CD4 counts above 350 cells/µl.](pmed.1001496.g014){#pmed-1001496-g014}

Two studies reported the CD4 counts of participants found to be HIV-positive in a key population. Using standard lab diagnostics these studies reported a median CD4 count of 550 cells/µl among MSM [@pmed.1001496-Champenois1] and 385 cells/µl among MSM, PWID, and FSW [@pmed.1001496-Bucher1].

Linkage to Care {#s4f}
---------------

17 studies, including 5,852 participants with HIV, reported linkage to care from HIV diagnosis to CD4 measurement [@pmed.1001496-Shapiro1],[@pmed.1001496-Chamie1],[@pmed.1001496-Kranzer1],[@pmed.1001496-Cherutich1],[@pmed.1001496-Dalal1],[@pmed.1001496-vanRooyen2],[@pmed.1001496-Feeley1],[@pmed.1001496-VanderBorght1],[@pmed.1001496-Patel1],[@pmed.1001496-Nglazi1],[@pmed.1001496-Govindasamy1]--[@pmed.1001496-Larson1],[@pmed.1001496-Naughton1],[@pmed.1001496-Wringe1]. Overall, 80.1% of participants had their CD4 count measured after HIV diagnosis (95% CI 74.8%--85.4%; *I* ^2^ 99.5%, 95% CI 99.4%--99.5%; [Figure 15](#pmed-1001496-g015){ref-type="fig"}). Nine studies with 527 participants reported linkage to care from being eligible to ART to initiating ART [@pmed.1001496-Shapiro1],[@pmed.1001496-Dalal1],[@pmed.1001496-vanRooyen2],[@pmed.1001496-Feeley1],[@pmed.1001496-Patel1],[@pmed.1001496-Govindasamy1],[@pmed.1001496-Wringe1]. Overall, 73.1% of participants initiated ART after their CD4 count indicated that they were eligible (95% CI 61.3%--84.9%; *I* ^2^ 96.9%, 95% CI 95.6%--97.9%; [Figure 15](#pmed-1001496-g015){ref-type="fig"}).

![Linkage to care with community-based approaches to HTC.\
Asterisk: study included 14 workplace sites in the Democratic Republic of Congo, Rwanda, Burundi, Congo, and Nigeria.](pmed.1001496.g015){#pmed-1001496-g015}

Two studies, including 52 participants with HIV, reported linkage to care from HIV diagnosis to CD4 measurement in key populations. 12 of 15 MSM had their CD4 count measured after HIV diagnosis [@pmed.1001496-Champenois1]. 26 of 37 MSM and/or PWID had their CD4 count measured after HIV diagnosis [@pmed.1001496-Bucher1]. No studies reported linkage to care from being eligible for ART to initiating ART in key populations.

Coverage {#s4g}
--------

14 studies summarised HTC coverage among all people living in the testing site\'s catchment area [@pmed.1001496-Sweat1],[@pmed.1001496-Chamie1],[@pmed.1001496-Lugada2],[@pmed.1001496-Kimaiyo1],[@pmed.1001496-Naik1],[@pmed.1001496-Negin1],[@pmed.1001496-Tumwesigye1],[@pmed.1001496-Wolff1]. Coverage of HTC ranged from 5% to 93% depending on the type of approach used ([Table 5](#pmed-1001496-t005){ref-type="table"}). Mobile HTC available as part of multi-disease health campaigns achieved high coverage in the shortest period of time. Community-based HTC increased coverage of HTC relative to facility-based approaches (RR 7.07, 95% CI 3.52--14.22; *I* ^2^ 99.7%, 95% CI 99.7%--99.8%; [Figure 9](#pmed-1001496-g009){ref-type="fig"}).

10.1371/journal.pmed.1001496.t005

###### Community coverage of voluntary HTC.
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  Study (Testing Approach)                                 Duration (Months)     Country      Year   Number Tested   Number Eligible   Percent Coverage
  ------------------------------------------------------- ------------------- -------------- ------ --------------- ----------------- ------------------
  Sweat (mobile) [@pmed.1001496-Sweat1]                           42             Thailand     2007      10,464           11,290              93%
  Lugada (mobile) [@pmed.1001496-Lugada2]                        0.23             Kenya       2008      47,173           51,178              92%
  Chamie (mobile) [@pmed.1001496-Chamie1]                        0.16             Uganda      2007       4,343            6,300              69%
  Wolff (door-to-door) [@pmed.1001496-Wolff1]                      1              Uganda      2001       1,078            1,591              68%
  Naik (door-to-door) [@pmed.1001496-Naik1]                       16           South Africa   2010       5,086            7,614              67%
  Kimaiyo (door-to-door) [@pmed.1001496-Kimaiyo1]                  7              Kenya       2009      90,062           143,284             63%
  Negin (door-to-door) [@pmed.1001496-Negin1]                     ---             Kenya       2008       1,984            3,180              62%
  Sweat (mobile) [@pmed.1001496-Sweat1]                           42             Zimbabwe     2007       6,579           10,700              61%
  Tumwesigye (door-to-door) [@pmed.1001496-Tumwesigye1]           30              Uganda      2007      264,966            ---               52%
  Sweat (mobile) [@pmed.1001496-Sweat1]                           37             Tanzania     2007       2,832            6,250              45%
  Sweat (facility-based) [@pmed.1001496-Sweat1]                   42             Thailand     2007       2,721           10,033              27%
  Sweat (facility-based) [@pmed.1001496-Sweat1]                   37             Tanzania     2007        685             6,733              10%
  Sweat (facility-based) [@pmed.1001496-Sweat1]                   42             Zimbabwe     2007        610            12,150               5%
  Wolff (facility-based) [@pmed.1001496-Wolff1]                   12              Uganda      2000        79              1,591               5%

---, data not reported.

HIV Incidence {#s4h}
-------------

One study reported HIV incidence [@pmed.1001496-Coates1]. There was a decreased risk of HIV infection in communities randomised to community-based testing relative to communities randomised to facility-based testing, although this estimate lacked statistical significance (RR 0.86, 95% CI 0.73--1.02; [Figure 9](#pmed-1001496-g009){ref-type="fig"}).

Cost per Person Tested {#s4i}
----------------------

The cost per person tested ranged from US\$2.45 to US\$881.63 using different community-based testing approaches ([Table 6](#pmed-1001496-t006){ref-type="table"}) [@pmed.1001496-Menzies1],[@pmed.1001496-Wykoff1],[@pmed.1001496-Negin1],[@pmed.1001496-Tumwesigye1],[@pmed.1001496-Grabbe1],[@pmed.1001496-Keenan1],[@pmed.1001496-Shrestha1],[@pmed.1001496-Kahn1]--[@pmed.1001496-Edgil1]. The cost per person tested was US\$2.45 to US\$14.37 for door-to-door testing, US\$3.26 to US\$33.54 for mobile testing, US\$12.91 for hospital testing, US\$15.30 to US\$203.04 for index testing, US\$21.28 to US\$29.56 for testing at a fixed HTC site, US\$126.48 for church-based testing, US\$92.83 to US\$881.63 for community-based testing for key populations, and US\$93.73 for testing at an HIV clinic. Due to the heterogeneity in health systems and HIV prevalence within and between countries, the cost per person identified with HIV was not included.

10.1371/journal.pmed.1001496.t006

###### Cost per person tested using different community-based testing approaches.
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  Study (Testing Approach)                                                              Country                                                  Components Included                                                Year   Number Tested   Total Costs (US Dollars)   Cost per Person Tested (US Dollars)   Cost per Person Tested (2012 US Dollars)
  ---------------------------------------------------------------------------------- -------------- -------------------------------------------------------------------------------------------------------------- ------ --------------- -------------------------- ------------------------------------- ------------------------------------------
  Molesworth (door-to-door) [@pmed.1001496-Molesworth1]                                  Malawi                                                    Testing supplies                                                 2007      11,172               \$26,019                         \$2.33                                   \$2.45
  Edgil (mobile) [@pmed.1001496-Edgil1]                                                Swaziland                                                   Testing supplies                                                 2011      152,000             \$486,834                         \$3.20                                   \$3.26
  Tumwesigye (door-to-door) [@pmed.1001496-Tumwesigye1]                                  Uganda                                    Testing supplies, personnel, and transportation                                  2007      52,342              \$367,792                         \$7.03                                   \$7.77
  Chamie (mobile) [@pmed.1001496-Chamie1]                                                Uganda                                       Testing supplies, personnel, and buildings                                    2012        ---                  ---                            \$8.27                                   \$8.27
  Menzies (door-to-door) [@pmed.1001496-Menzies1]                                        Uganda          Testing supplies, personnel, transportation, vehicles, buildings, utilities, training, and equipment       2007        ---                  ---                            \$8.29                                   \$9.16
  Negin (door-to-door) [@pmed.1001496-Negin1]                                            Kenya                                     Testing supplies, personnel, and transportation                                  2008       1,984               \$17,569                         \$8.86                                   \$9.43
  Kahn (mobile)[a](#nt106){ref-type="table-fn"} [@pmed.1001496-Kahn1]                    Kenya                             Testing supplies, personnel, training, and contingency expenses                          2008        ---                  ---                            \$9.91                                  \$10.55
  Helleringer (door-to-door) [@pmed.1001496-Helleringer1]                                Malawi                    Testing supplies, personnel, transportation, buildings, utilities, and training                  2007       1,183               \$15,181                         \$12.83                                 \$14.37
  Menzies (hospital) [@pmed.1001496-Menzies1]                                            Uganda          Testing supplies, personnel, transportation, vehicles, buildings, utilities, training, and equipment       2007        ---                  ---                            \$11.68                                 \$12.91
  Menzies (index) [@pmed.1001496-Menzies1]                                               Uganda          Testing supplies, personnel, transportation, vehicles, buildings, utilities, training, and equipment       2007        ---                  ---                            \$13.85                                 \$15.30
  Grabbe (mobile) [@pmed.1001496-Grabbe1]                                                Kenya                        Testing supplies, personnel, vehicles, buildings, utilities, and equipment                    2007        ---                  ---                            \$14.91                                 \$16.47
  Menzies (fixed HTC site) [@pmed.1001496-Menzies1]                                      Uganda          Testing supplies, personnel, transportation, vehicles, buildings, utilities, training, and equipment       2007        ---                  ---                            \$19.26                                 \$21.28
  Grabbe (fixed HTC site) [@pmed.1001496-Grabbe1]                                        Kenya                        Testing supplies, personnel, vehicles, buildings, utilities, and equipment                    2007        ---                  ---                            \$26.75                                 \$29.56
  Terris-Prestholt (mobile) [@pmed.1001496-TerrisPrestholt1]                             Uganda                            Testing supplies, personnel, vehicles, buildings, and equipment                          2001       4,425              \$114,761                         \$25.93                                 \$33.54
  McConnel (church) [@pmed.1001496-McConnel1]                                         South Africa      Testing supplies, personnel, utilities, training, buildings, office equipment, and publicity materials      2003        662                \$67,248                        \$101.58                                 \$126.48
  Keenan (mobile for MSM, PWID, and FSW) [@pmed.1001496-Keenan1]                           US                                      Testing supplies, personnel, and transportation                                  2001        735                \$52,744                         \$71.76                                 \$92.83
  Shrestha (HIV clinic) [@pmed.1001496-Shrestha1]                                          US        Testing and office supplies, personnel, transportation, utilities, building, vehicles, and recruitment costs   2005        855                \$68,318                         \$79.90                                 \$93.73
  Shrestha (mobile for MSM, PWID, and FSW) [@pmed.1001496-Shrestha1]                       US        Testing and office supplies, personnel, transportation, utilities, building, vehicles, and recruitment costs   2005       1,679              \$276,218                        \$164.51                                 \$192.98
  Wykoff (index) [@pmed.1001496-Wykoff1]                                                   US                                      Testing supplies, personnel, and transportation                                  1988        62                 \$6,500                         \$104.84                                 \$203.04
  Shrestha (mobile for transgender individuals and PWID) [@pmed.1001496-Shrestha3]         US                Testing and office supplies, personnel, transportation, building, utilities, and incentives            2007        301               \$190,202                        \$631.90                                 \$698.22
  Shrestha (mobile for MSM and PWID) [@pmed.1001496-Shrestha2]                             US                           Testing and office supplies, personnel, transportation, and incentives                      2007        817               \$651,873                        \$797.89                                 \$881.63

Cost included CD4 measurement and 60 condoms.

---, data not reported.

Potential Harms {#s4j}
---------------

No studies reported harm arising as a result of having been tested. 18 studies gave a description of the testers\' experiences or listed reasons for tester refusal [@pmed.1001496-Choko1]--[@pmed.1001496-Spielberg1],[@pmed.1001496-Chirawu1],[@pmed.1001496-Ostermann1],[@pmed.1001496-Kranzer2],[@pmed.1001496-Negin1],[@pmed.1001496-Wolff1],[@pmed.1001496-Feeley1],[@pmed.1001496-Outlaw1],[@pmed.1001496-Bell1],[@pmed.1001496-Morin1],[@pmed.1001496-Bingham1],[@pmed.1001496-Champenois1],[@pmed.1001496-Jurgensen1]--[@pmed.1001496-Nuwaha1]. The studies discussed both the clients\' positive testing experiences and their fears. Eight studies (including one targeting key populations) reported instances where participants refused HTC because of fear of status disclosure or stigma [@pmed.1001496-Chirawu1],[@pmed.1001496-Ostermann1],[@pmed.1001496-Kranzer2],[@pmed.1001496-Negin1],[@pmed.1001496-Wolff1],[@pmed.1001496-Feeley1],[@pmed.1001496-Bell1],[@pmed.1001496-Morin1]. In contrast, 12 studies (including three studies targeting key populations) specifically reported either no evidence of harm [@pmed.1001496-Choko1]--[@pmed.1001496-Spielberg1],[@pmed.1001496-Kranzer1],[@pmed.1001496-Outlaw1],[@pmed.1001496-Bingham1],[@pmed.1001496-Champenois1] or benefit through improved privacy or reduced stigma and fear [@pmed.1001496-Chirawu1],[@pmed.1001496-Feeley1],[@pmed.1001496-Jurgensen1]--[@pmed.1001496-Nuwaha1].

Quality Assessment {#s4k}
------------------

There was concern of selection bias in nine of the studies included in pooled analyses [@pmed.1001496-Corbett1],[@pmed.1001496-Sweat1],[@pmed.1001496-Gonzalez1],[@pmed.1001496-Spielberg3],[@pmed.1001496-Hood1],[@pmed.1001496-Granich1], concern of confounding in five studies [@pmed.1001496-Ahmed1],[@pmed.1001496-Gonzalez1],[@pmed.1001496-Lahuerta1],[@pmed.1001496-Spielberg3],[@pmed.1001496-Hood1], and concern of measurement bias in five studies [@pmed.1001496-Wolff1],[@pmed.1001496-Grabbe1],[@pmed.1001496-Spielberg3],[@pmed.1001496-vanSchaik1],[@pmed.1001496-Wachira1] ([Table S2](#pmed.1001496.s003){ref-type="supplementary-material"}). The randomised trials appeared to have limited selection, attrition, and reporting bias; however, their lack of blinding made them susceptible to performance and detection bias [@pmed.1001496-Corbett1],[@pmed.1001496-Sweat1] ([Table S3](#pmed.1001496.s004){ref-type="supplementary-material"}).

Sensitivity Analyses {#s4l}
--------------------

While there was high uptake for community-based approaches in most studies, there were several outliers with low uptake. To gauge whether these outliers influenced pooled uptake estimates and increased heterogeneity we conducted sensitivity analyses without them ([Table 7](#pmed-1001496-t007){ref-type="table"}). Although the pooled estimates increased and the CIs tightened without the outliers, there was still high heterogeneity using the *I* ^2^ statistic. There was potential for selection bias, confounding, and measurement bias in several of the observational studies identified ([Table S2](#pmed.1001496.s003){ref-type="supplementary-material"}). To determine whether these studies introduced bias into our results we ran sensitivity analyses without them and found the results to be similar ([Table 8](#pmed-1001496-t008){ref-type="table"}).

10.1371/journal.pmed.1001496.t007

###### Pooled relative risks of community- versus facility-based HTC sensitivity analyses.

![](pmed.1001496.t007){#pmed-1001496-t007-7}

  Outcome                             Pooled RR (95% CI)    *I^2^* Statistic                                                                                        Observational Studies Removed                                                                                         Revised Pooled Estimate (95% CI)   Revised *I^2^* Statistic
  ---------------------------------- --------------------- ------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------- --------------------------
  Uptake                              10.65 (6.27--18.08)        96.1%                                                                                                 [@pmed.1001496-Lugada1]                                                                                                  13.99 (11.75--16.68)                   N/A
  Proportion of first-time testers     1.23 (1.06--1.42)         99.8%                                               [@pmed.1001496-Ahmed1],[@pmed.1001496-Menzies1],[@pmed.1001496-Grabbe1],[@pmed.1001496-Lahuerta1],[@pmed.1001496-Spielberg3]                                                1.12 (0.91--1.38)                    99.9%
  HIV positivity rate                  0.59 (0.37--0.96)         99.6%         [@pmed.1001496-Ahmed1],[@pmed.1001496-Menzies1],[@pmed.1001496-Lugada1],[@pmed.1001496-Gonzalez1],[@pmed.1001496-HenryReid1],[@pmed.1001496-Lahuerta1],[@pmed.1001496-Hood1]--[@pmed.1001496-vanSchaik1]          0.47 (0.22--1.02)                    99.6%
  Coverage                            7.07 (3.52--14.22)         99.7%                                                                                                  [@pmed.1001496-Wolff1]                                                                                                   5.71 (2.63--12.40)                   99.8%

N/A, not applicable.

10.1371/journal.pmed.1001496.t008

###### Pooled uptake proportion sensitivity analyses.

![](pmed.1001496.t008){#pmed-1001496-t008-8}

  HTC Approach    Pooled Estimate (95% CI)   *I^2^* Statistic                                                        Outliers Removed                                                        Revised Pooled Estimate (95% CI)   Revised *I^2^* Statistic
  -------------- -------------------------- ------------------ ---------------------------------------------------------------------------------------------------------------------------- ---------------------------------- --------------------------
  Index              88.2 (80.5--95.9)            99.7%                                                          [@pmed.1001496-Shapiro1]                                                           93.5 (89.1--97.9)                    99.0%
  Mobile             86.8 (85.6--88.1)            99.9%                                 [@pmed.1001496-Slesak1],[@pmed.1001496-Chirawu1],[@pmed.1001496-Darling1]                                   97.9 (97.6--98.3)                    98.5%
  Door-to-door       80.0 (76.9--83.1)            99.9%         [@pmed.1001496-Shapiro1],[@pmed.1001496-Molesworth1],[@pmed.1001496-Vreeman1],[@pmed.1001496-Welz1],[@pmed.1001496-Wolff1]          84.2 (81.8--86.6)                    99.9%
  Workplace          67.4 (32.8--100.0)            100%                                                       [@pmed.1001496-VanderBorght1]                                                         76.9 (61.8--92.0)                    99.8%
  School             62.1 (39.6--84.5)            99.0%                                                         [@pmed.1001496-HenryReid1]                                                          71.9 (46.4--97.3)                    99.4%

Outliers were defined as study estimates more than one standard deviation away from the pooled estimate.

Discussion {#s5}
==========

This systematic review found that community-based HTC approaches were successful in reaching populations early in the course of HIV infection. The studies with facility-based comparator arms further suggest that community-based HTC reached populations earlier in the course of HIV infection than facility-based HTC. Earlier HIV diagnosis supports timely access to ART, which could improve life expectancy and reduce HIV transmission [@pmed.1001496-Tanser1]--[@pmed.1001496-Bor1]. Earlier HIV diagnosis linked to ART may also have important socioeconomic effects at the population level, including (1) reducing the number of orphans [@pmed.1001496-Anema1], (2) improving education and employment outcomes [@pmed.1001496-Thirumurthy1],[@pmed.1001496-Bor2], and (3) increasing the size of workforces [@pmed.1001496-Risley1],[@pmed.1001496-Ventelou1].

The HIV positivity rate among participants in community-based HTC approaches was generally lower than that among participants in facility-based HTC. This could be because (1) symptomatic people with HIV are more likely to visit health facilities, (2) healthcare workers are more likely to offer HTC to patients with symptoms that might be associated with HIV, and (3) the positivity rate of participants in community-based HTC is more likely to be representative of the general population. While obtaining a lower positivity rate may immediately be associated with increased numbers needing to be tested to identify people with HIV, community-based HTC increased the number of newly diagnosed people with HIV 4-fold in a randomised controlled trial, has the potential to decrease HIV stigma by normalising HIV testing, and is an opportunity to provide prevention interventions for HIV and other diseases to asymptomatic populations [@pmed.1001496-Sweat1],[@pmed.1001496-Chirawu1],[@pmed.1001496-Feeley1],[@pmed.1001496-Jurgensen1]--[@pmed.1001496-Nuwaha1]. The HIV positivity rate among key populations utilising community-based testing varied relative to the HIV positivity rate among key populations utilising facility-based HTC and requires further examination within different epidemiological contexts. Although few comparative cost data exist on the various HTC approaches, the reported estimates indicate that several community-based testing approaches are cheaper or similarly priced compared to facility-based HTC ([Table 6](#pmed-1001496-t006){ref-type="table"}).

Because many settings lack universal health coverage, other disease control strategies---such as the guinea worm eradication campaign [@pmed.1001496-Hopkins1], eradication campaigns against polio and measles [@pmed.1001496-deQuadros1],[@pmed.1001496-deQuadros2], and efforts to eliminate preventable blindness [@pmed.1001496-Natchiar1]---are built upon community-based elements for broader reach. Since community outreach efforts for these disease control strategies have largely been vertical in nature, some have suggested leveraging community-based HTC as a conduit for delivering other public health activities based on national burden of disease [@pmed.1001496-Suthar2]. Multi-disease approaches may include the provision of vaccines, water filters, and malaria bed nets and screening for cardiovascular disease, diabetes, and pulmonary disease [@pmed.1001496-World3]. Settings implementing recent WHO guidance on community-based screening for tuberculosis and malaria could also consider multi-disease frameworks to improve efficiency [@pmed.1001496-World4],[@pmed.1001496-World5]. Including other public health activities based on national epidemiology, such as family planning and viral hepatitis screening and treatment, may also be appropriate. Indeed, 40 of the 117 studies meeting this review\'s eligibility criteria (34%) had a multi-disease component. Broadening community-based HTC to include preventive interventions and screening for other diseases could further improve cost-effectiveness [@pmed.1001496-Kahn2].

In the studies reviewed, HTC uptake exceeded 80% in the mobile, index, self, and door-to-door testing approaches. While workplace and school-based testing could be an important approach in some settings, the uptake of these approaches was lower than that of other community-based approaches. Further research may improve their acceptability and could evaluate their impact on employment and education outcomes. Although there was no evidence of any harm resulting from being tested in community-based HTC approaches, there were reports of fear of status disclosure or stigma. Moreover, a recent report highlights the possibility of false positive diagnoses in settings (1) lacking a confirmation HIV test, (2) with poor training and supervision of community health workers, and (3) with insufficient quality control procedures [@pmed.1001496-Shanks1]. These findings highlight the continuing need to adhere to validated testing algorithms and to address legal and human rights issues, and for the 5 Cs of good testing practices---informed consent, confidentiality, counselling, correct test results, and connection to prevention and care---to always be present [@pmed.1001496-World2].

There was variable uptake for community-based testing among key populations. The heterogeneity between studies likely relates to differences in the way HTC was offered. For example, the studies with the lowest uptake among key populations offered HTC only in combination with extensive behavioural surveys [@pmed.1001496-Spielberg2],[@pmed.1001496-Galvan1]. The findings from this small number of studies cannot be generalised widely. Moreover, there were limited CD4 count and ART linkage data from these studies, indicating that caution may be needed when providing HTC to key populations in settings where they remain marginalised and stigmatised and where there are inadequate linkages to prevention and care services. It is also important to safeguard confidentiality and prevent possible coercion, discrimination, and other adverse consequences for key populations being offered HTC in community settings. Further operational research on community-based testing for key populations, including mobile peer-based models [@pmed.1001496-McCoy1],[@pmed.1001496-Shrestha2],[@pmed.1001496-Kimbrough1],[@pmed.1001496-Ti1], within this human rights framework is needed.

One of the benefits of community-based testing, especially door-to-door testing, is allowing couples and families to be counselled about their HIV status, behaviour change, ART, and prevention interventions together [@pmed.1001496-World6],[@pmed.1001496-World7]. Review of population-level HTC efforts suggest that implementation of community-based HTC could increase the number of couples receiving testing ([Table 2](#pmed-1001496-t002){ref-type="table"}). There were relatively limited data on HTC approaches for infants, children and adolescents. The door-to-door, mobile, school, and index community-based approaches have promise for these young populations, but further research could improve their operationalisation [@pmed.1001496-Lugada1],. In addition to implementing provider-initiated HTC in all health facilities in generalised epidemics, introducing HIV testing at scheduled immunisation visits may facilitate earlier diagnosis linked to care [@pmed.1001496-Binagwaho1].

Offering community-based HTC in addition to facility-based HTC increased knowledge of HIV status approximately 7-fold at the population level. Providing near universal knowledge of HIV status linked to prevention and care may impact HIV transmission networks through increased coverage of ART, increased male circumcision prevalence, increased utilisation of needle exchange programmes, increased utilisation of condoms, increased utilisation of pre-exposure prophylaxis, behavioural change, and increased coverage of opiate substitution therapy. A cluster-randomised trial detected a statistically non-significant 14% reduction in population incidence in communities where community-based HTC was available [@pmed.1001496-Coates1]. Since community-based HTC wasn\'t directly linked to prevention and care services in this trial, achieving and maintaining high levels of HTC coverage and maximising linkage to ART and other components of combination prevention could lead to more substantial reductions in population incidence [@pmed.1001496-Granich2]--[@pmed.1001496-Granich3].

Incidence reductions depend on high coverage of repeat testing among people at risk of HIV infection. WHO recommends that HIV-negative individuals with ongoing sexual behaviour and/or who inject drugs with partners of positive or unknown HIV status should be tested at least annually [@pmed.1001496-World8]. A high percentage of people reported being first-time testers with community-based approaches, and overall there was a higher proportion of first-time testers in community-based approaches than in facility-based approaches. In effective HTC programmes, the proportion of people reporting receiving their first test should decrease over time as a result of implementing WHO repeat testing recommendations [@pmed.1001496-Helleringer1]. Several studies assessed uptake in the context of repeat testing. In several generalised epidemic settings, uptake remained high among the general population [@pmed.1001496-Angotti1],[@pmed.1001496-Helleringer1]. Conversely, uptake decreased among the general population in a concentrated epidemic, suggesting that HTC may need to be targeted to key populations on an ongoing basis in these settings [@pmed.1001496-Slesak1].

This review found that 80% of participants in the community-based HTC studies where CD4 measurement was offered had their CD4 count measured after HIV diagnosis. CD4 measurement was facilitated by (1) point-of-care CD4 diagnostics, (2) collection of blood samples at the time of diagnosis, and (3) workplace programmes that had regular contact with participants because of their work schedules. This percentage was similar to the percentages reported in two systematic reviews evaluating CD4 measurement from facility-based testing (59%--72%) [@pmed.1001496-Mugglin1],[@pmed.1001496-Rosen1], and supports the notion that high uptake of CD4 measurement can be achieved outside of health facilities when it is offered in combination with testing results. This review also found that 73% of participants initiated ART after their CD4 counts indicated that they were eligible. This proportion was comparable to previous estimates from two systematic reviews evaluating ART initiation rates from healthcare facilities (62%--68%) [@pmed.1001496-Mugglin1],[@pmed.1001496-Rosen1]. Linkage from community-based HTC approaches to community-based treatment programmes could improve ART access and uptake and merits further exploration [@pmed.1001496-Jaffar1]--[@pmed.1001496-Selke1]. The data on linkage to prevention services, including linking men with negative results to male circumcision [@pmed.1001496-Mahler1], were very limited. These linkages will be required to maximise the population benefits of community-based testing. Additional data on linkage to prevention services are urgently needed. Because self-testing achieves anonymous knowledge of status, no studies have been able to provide data on rates of linkage to care or prevention for people using this testing approach [@pmed.1001496-PantPai1]. Nonetheless, self-testing may provide programmatic advantages in some settings and requires further research [@pmed.1001496-World9].

There are some methodological limitations that need to be considered when evaluating the impact of community-based HTC. One of the outcomes, first-time tester proportion, has potential for recall bias since it relies on participants to recall their history of HIV testing. Since all of the studies that included a facility-based HTC comparator arm did not indicate whether HTC was provider- or client-initiated, comparisons were made to facility-based HTC approaches irrespective of who initiated the interaction. Therefore, this review may not provide conclusive evidence of community-based HTC relative to provider-initiated HTC. While 73% of participants initiated ART after their CD4 count indicated they were eligible, all of the studies providing these data did not provide information on the timing of this outcome. Understanding how soon after diagnosis participants were able to initiate ART could help establish the efficiency of linkage systems. While this review summarises information from different community-based testing approaches globally, only six of the 117 studies identified were from Asia, indicating a need to expand community-based HTC research efforts in this region. Finally, given the complexity and expense of conducting cluster-randomised controlled trials, most of the studies meeting the eligibility criteria were observational. Although our analyses included data from randomised controlled trials, the potential for unmeasured confounding in observational studies makes attempts to establish causal effect more difficult.

The meta-analyses may have limitations in the statistical methodology used. Using the *I* ^2^ statistic, there was high heterogeneity for most meta-analyses. All analyses should be interpreted with respect to local epidemiology, social and cultural context, and the health systems organisation of the studies contributing data. Publication bias was not formally assessed, as analytical methods to test for publication bias, such as funnel plots and funnel plot asymmetry tests, may not be appropriate for observational data [@pmed.1001496-Tang1]. Multiple study estimates and standardised variable definitions are required to explore the contributors of heterogeneity for pooled estimates. Given that the same variables were not collected systematically in all studies, this assessment was not undertaken for this review.

In conclusion, many community-based approaches achieved high uptake of HTC. Costs and linkage to care appeared similar to those of facility-based HTC approaches. The lower yield of people with HIV relative to facility-based HTC approaches appears to be offset by increasing knowledge of status at the population level, which, combined with timely linkage to treatment and prevention services, could have population effects on life expectancy and HIV transmission. As countries develop their new national strategic plans and investment cases based on WHO and Joint United Nations Programme on HIV/AIDS strategic guidance [@pmed.1001496-Schwartlander1], consideration should be given to increasing the proportion of people with HIV who know their status, with linkages to prevention and care, by offering community-based testing in addition to facility-based testing [@pmed.1001496-World10].
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